To Be Discontinued Tablet Neurology

Lasmiditan Succinate Tablet · 312 days since initial FDA posting

Brand: REYVOW

FDA lists Lasmiditan Succinate Tablet as To Be Discontinued (Eli Lilly and Co.).

No availability text on this FDA row.

Lasmiditan Succinate Tablet: To Be Discontinued

FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.

Shortage Details

Generic Name
Lasmiditan Succinate Tablet
Manufacturer
Eli Lilly and Co.
Dosage Form
Tablet
Presentation
Reyvow, Tablet, 100 mg (NDC 0002-4491-61)
Package NDC
0002-4491-61

Status & Timeline

Status
To Be Discontinued
First Reported
Nov 3, 2025
Last Updated
Nov 3, 2025
Therapeutic Category
Neurology

Row fields from the FDA Drug Shortages database via openFDA.

Shortage Reason

A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.

Nearby, Other Lasmiditan Shortage Records

Lasmiditan Succinate Tablet

Eli Lilly and Co.

Tablet

To Be Discontinued

Lasmiditan Succinate Tablet

Eli Lilly and Co.

Tablet

To Be Discontinued

Lasmiditan Succinate Tablet

Eli Lilly and Co.

Tablet

To Be Discontinued

Lasmiditan Succinate Tablet

Eli Lilly and Co.

Tablet

To Be Discontinued

Lasmiditan Succinate Tablet

Eli Lilly and Co.

Tablet

To Be Discontinued

FDA reason on file: A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. General shortage guidance lives on the tracker hub.

← All Drug Shortages